Analysis of cleavage complexes using reactive inhibitor derivatives.
Kreuzer
K N
KN
Department of Microbiology, Duke University Medical Center, Durham, NC, USA.
Freudenreich
C H
CH
Pommier
Y
Y
D000478:Alkylation; D000677:Amsacrine / Q000031:analogs & derivatives / Q000737:chemistry / Q000378:metabolism*; D000818:Animals; D017122:Bacteriophage T4 / Q000201:enzymology; D001483:Base Sequence; D001665:Binding Sites; D002166:Camptothecin / Q000031:analogs & derivatives / Q000737:chemistry / Q000378:metabolism*; D002417:Cattle; D004247:DNA / Q000737:chemistry / Q000378:metabolism*; D004264:DNA Topoisomerases, Type I / Q000378:metabolism; D004250:DNA Topoisomerases, Type II / Q000378:metabolism; D006801:Humans; D007364:Intercalating Agents / Q000737:chemistry / Q000378:metabolism; D008027:Light; D015394:Molecular Structure; D009838:Oligodeoxyribonucleotides / Q000737:chemistry / Q000378:metabolism; D010777:Photochemistry; D010920:Placenta / Q000201:enzymology; D011485:Protein Binding; D013950:Thymus Gland / Q000201:enzymology; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors
D007364:Intercalating Agents; D009838:Oligodeoxyribonucleotides; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D000677:Amsacrine; D004247:DNA; D004264:DNA Topoisomerases, Type I; D004250:DNA Topoisomerases, Type II; D002166:Camptothecin